GlassScriptPhysician profile
Lee B Taylor
NPI 1003863929
$3,697.10
in general payments reported to CMS, 2019-2025
35 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $336 · 2021: $1,086 · 2022: $747 · 2023: $582 · 2024: $324 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.23 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.10 | 2021-2024 | Dalvance, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $357.31 | 2019-2023 | |
| Esperion Therapeutics, INC. | $343.40 | 2020-2021 | |
| Amgen INC. | $323.02 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Abbott Laboratories | $279.27 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $250.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $227.40 | 2020-2023 | Farxiga, Flumist Quadrivalent |
| Janssen Pharmaceuticals, INC | $203.09 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $168.37 | 2019-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $126.37 | 2019-2024 | Shingrix |
| Baxter Healthcare | $84.29 | 2022 | |
| Amarin Pharma, INC. | $81.34 | 2019-2020 | |
| Abiomed | $78.14 | 2024-2025 | Impella |
| Corium, LLC | $72.00 | 2022-2025 | Azstarys |
| Sumitomo Pharma America, INC. | $59.02 | 2023-2024 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55.31 | 2019-2022 | |
| Pfizer INC. | $54.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $51.30 | 2021-2022 | |
| Novo Nordisk INC | $50.20 | 2021-2025 | Ozempic, Rybelsus |
| Inari Medical, INC. | $46.33 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kowa Pharmaceuticals America, INC. | $30.82 | 2022 | |
| Atricure, INC. | $27.36 | 2024 | |
| Lilly USA, LLC | $26.33 | 2022-2024 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.83 | 2020-2021 | |
| Dexcom, INC. | $24.03 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $20.12 | 2021 | |
| Philips North America LLC | $19.80 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.22 | 2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $13.89 | 2021 | |
| Medtronic, INC. | $13.83 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.63 | 2023 | Quviviq |
| Intuity Medical INC | $13.55 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Acadia Pharmaceuticals INC | $11.60 | 2021 | |
| Allergan, INC. | $11.30 | 2020 | |
| Travere Therapeutics, INC. | $2.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.